A randomized, double-blind, placebo-controlled, single-ascendingdose and two-way crossover food effect study to determine the safety, tolerability, pharmacokinetics and food effect of ATN-249 in healthy male participants

Trial Profile

A randomized, double-blind, placebo-controlled, single-ascendingdose and two-way crossover food effect study to determine the safety, tolerability, pharmacokinetics and food effect of ATN-249 in healthy male participants

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs ATN 249 (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Attune Pharmaceuticals
  • Most Recent Events

    • 26 Mar 2018 Status changed from planning to not yet recruiting.
    • 09 Mar 2017 New trial record
    • 07 Mar 2017 Acording to Attune Pharmaceuticals media release, company expects to start the trial in middle of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top